Trial Profile
Cabazitaxel in Platinum Pre-treated Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma Who Developed Disease Progression Within 12 Months of Platinum Based Chemotherapy.
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 19 Oct 2022
Price :
$35
*
At a glance
- Drugs Cabazitaxel (Primary) ; Antineoplastics
- Indications Bladder cancer; Carcinoma
- Focus Therapeutic Use
- Acronyms CabB1
- 06 Jun 2017 Results (n=20) assessing efficacy of Cabazitaxel, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
- 26 Feb 2013 Planned end date changed from 1 Dec 2015 to 31 Dec 2015 as reported by ISRCTN: Current Controlled Trials record.
- 26 Feb 2013 New source identified and integrated (ISRCTN: Current Controlled Trials; 76947550).